These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12790512)

  • 21. Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.
    Marcellin P; Horsmans Y; Nevens F; Grange JD; Bronowicki JP; Vetter D; Purdy S; Garg V; Bengtsson L; McNair L; Alam J
    J Hepatol; 2007 Oct; 47(4):476-83. PubMed ID: 17629590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C virus: standard-of-care treatment.
    Pawlotsky JM
    Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with efficacy of pegylated interferon-α plus ribavirin for chronic hepatitis C after renal transplantation.
    Li LF; Shi KQ; Lin YQ; Wang LR; He JP; Braddock M; Chen YP; Zheng MH
    Gene; 2014 Jul; 544(2):101-6. PubMed ID: 24793583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current treatment for chronic hepatitis C virus/HIV-infected individuals: the role of pegylated interferon-alpha and ribavirin.
    Bhagani S
    Curr Opin HIV AIDS; 2011 Nov; 6(6):483-90. PubMed ID: 22001893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action.
    Paeshuyse J; Dallmeier K; Neyts J
    Curr Opin Virol; 2011 Dec; 1(6):590-8. PubMed ID: 22440916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic hepatitis C virus infection in 2013--quo vadis?
    Prelipcean CC; Mihai C
    Rev Med Chir Soc Med Nat Iasi; 2013; 117(1):7-10. PubMed ID: 24505885
    [No Abstract]   [Full Text] [Related]  

  • 28. Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication.
    Li S; Kodama EN; Inoue Y; Tani H; Matsuura Y; Zhang J; Tanaka T; Hattori T
    Antivir Chem Chemother; 2010 Aug; 20(6):239-48. PubMed ID: 20710064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treating HCV with ribavirin analogues and ribavirin-like molecules.
    Gish RG
    J Antimicrob Chemother; 2006 Jan; 57(1):8-13. PubMed ID: 16293677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
    Rodríguez-Torres M
    Expert Rev Anti Infect Ther; 2013 Dec; 11(12):1269-79. PubMed ID: 24215243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of ribavirin in patients with chronic HCV genotype 1: when enough is really enough.
    Shiffman ML; Rustgi VK
    Gastroenterology; 2006 Oct; 131(4):1339-41. PubMed ID: 17030201
    [No Abstract]   [Full Text] [Related]  

  • 34. [The role of ribavirin in the treatment of chronic hepatitis C].
    Pawłowska M
    Przegl Epidemiol; 2008; 62(1):143-7. PubMed ID: 18536237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serine protease inhibitors as anti-hepatitis C virus agents.
    Reiser M; Timm J
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):537-47. PubMed ID: 19485794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of chronic hepatitis C.
    Bihl F; Negro F
    Minerva Med; 2009 Dec; 100(6):459-65. PubMed ID: 20010481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ribavirin in the treatment of chronic hepatitis C.
    Martin P; Jensen DM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):844-55. PubMed ID: 18565019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy.
    Esmat GE; Al Akel W; Abdel Aziz RA; Al Sayed Taha A; Sabry D; Rashed LA; Mostafa A; El Kazaz AY; Ahmed SH
    J Interferon Cytokine Res; 2016 Mar; 36(3):149-58. PubMed ID: 26982165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: novel therapeutic options for chronic hepatitis C.
    Cholongitas E; Papatheodoridis GV
    Aliment Pharmacol Ther; 2008 May; 27(10):866-84. PubMed ID: 18284651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.